Citizens JMP analyst Reni Benjamin initiated coverage of Compass Therapeutics (CMPX) with an Outperform rating and $10 price target The firm says the company’s most-advanced candidate, tovecimig, recently demonstrated a 17% overall response rate in combination with paclitaxel as a treatment for biliary tract cancers versus 5% for the paclitaxel comparison arm in a pivotal Phase 2/3 study. The analyst also believes CTX-10726 “could be a diamond in the rough” for Compass.
Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CMPX:
- Compass Therapeutics’ CTX-10726: A Promising Leader in the Competitive PD-1 and VEGF Markets
- Compass Therapeutics Reports Q3 2025 Financial Results
- Positive Outlook for Compass Therapeutics: Buy Rating Justified by Promising Developments and Strong Financial Position
- Compass Therapeutics reports Q3 EPS (8c), consensus (13c)
- Compass Therapeutics presents preclinical data on CTX-10726